Former Full House star Dave Koulier revealing today he has tongue cancer just a little under a year since he beat lymphoma. He told the Today Show the diagnosis was a big shocker and he's currently going through treatment. ...

Full House star Dave Coulier diagnosed with tongue cancer https://t.co/p3lHitajEy ...

I saw you first in Zurich when you received the chemical engineering medal when I was doing my PhD and then uh we met there briefly and later on I had a conference in Boston and I said well I was fascinated by you know Bob's fascination for polymer science. I'm a polymer scientist as well and like Bob said uh you can use polymers they typically are used in the plastic industry and for the first time you were thinking you know way back can we use it for drug delivery and so I thought that was very inspiring ...

An almost unrecognizable Tatiana Schlloberg sits with her legs crossed and her hands pressed together, no longer able to hide her brittle bones and thinning hair. As she bravely shared in The New Yorker, her body has been ravaged by a rare form of blood cancer called acute myoid leukemia. The touching piece entitled A Battle with My Blood documents the fight for her life. Doctors telling former President John F. Kennedy's granddaughter just a short time ago. She may only have a year left to live. >> I suspe ...

[Musique] Est-ce que vous aussi vous avez déjà désiré tellement quelque chose que vous aviez l'impression que de ne pas réaliser votre rêve pouvait vous empêcher de respirer correctement ? Avez-vous déjà ressenti une telle tristesse de ne pas pouvoir avoir ce que vous désiriez le plus ? Que vous aviez l'impression que personne ne vous comprenait ? J'ai toujours été volontaire, persévérante. Ma mère disait que je ne lâchais jamais. La persévérance me permettait en effet de dépasser mes limites et d'obtenir c ...

From @WSJopinion: With continued investment in mRNA research, Donald Trump could turn the stalemate against cancer into a decisive breakthrough, writes Jeff Coller https://t.co/DDBtbYJKy4 ...

From @WSJopinion: With continued investment in mRNA research, Donald Trump could turn the stalemate against cancer into a decisive breakthrough, writes Jeff Coller https://t.co/jCCaRSBCrQ ...

Core Insights - Rigel Pharmaceuticals reported strong third-quarter performance, leading to an increase in full-year 2025 revenue guidance due to outstanding commercial execution and pipeline development [2][10]. Financial Performance - Total revenues for Q3 2025 were $69.5 million, comprising $64.1 million in net product sales (up 65% from $38.9 million in Q3 2024) and $5.4 million in contract revenues [4][10]. - Net product sales for TAVALISSE reached $44.7 million (70% growth), GAVRETO at $11.1 million (56% growth), and REZLIDHIA at $8.3 million (50% growth) compared to the same period in 2024 [4][11]. - For the nine months ended September 30, 2025, total revenues were $224.5 million, with net product sales growing 69% year-over-year [7]. Costs and Expenses - Total costs and expenses for Q3 2025 were $41.0 million, slightly down from $41.3 million in Q3 2024, primarily due to lower costs of product sales [5][10]. - Research and development costs increased due to clinical activities related to olutasidenib and R289, along with higher personnel-related costs [5][8]. Net Income - Rigel reported a net income of $27.9 million for Q3 2025, compared to $12.4 million in Q3 2024, translating to $1.55 basic and $1.46 diluted earnings per share [6][10]. Cash Position - As of September 30, 2025, cash, cash equivalents, and short-term investments totaled $137.1 million, up from $77.3 million at the end of 2024 [9][10]. Clinical Development - Rigel is advancing its Phase 1b study of R289 for lower-risk MDS, with enrollment completed in the dose escalation phase and the first patient enrolled in the dose expansion phase [2][11]. - Updated data from the R289 study will be presented at the ASH Annual Meeting in December [10][11]. 2025 Outlook - The company updated its 2025 revenue guidance to approximately $285 to $290 million, an increase from the previous estimate of $270 to $280 million [12][24]. - Rigel anticipates reporting positive net income for the full year 2025 while funding existing and new clinical development programs [12].

Johnson & Johnson has seen a 17% jump in new lawsuits claiming its iconic baby powder causes cancer after the company’s latest attempt to force a global settlement was thrown out of bankruptcy court https://t.co/IUX0azCloD ...

It is time round by social just and then the lightning round is over. Are you ready. Ski daddy the lightning round.Let's go to John in South Carolina. John, >> how you doing Jim. Couldn't be better.John, how about you. >> Doing fine down here in South Kakalaki. >> Yeah.Okay. What stock. >> BL.Yeah. Okay. Building stock.I can't I think the stock is well ahead of where it should be. Even though I like the company, the rest of the cohort is down. I would do some trimming of that stock.How about we go to Nichol ...